Clinical studies using IL-2 immunocytokines, particularly in combination setting with other biopharmaceuticals, have demonstrated efficacy in inducing anti-tumor immune responses mediated by CD8+ T cells, NK cells, and macrophages (https://www.clinicaltrials.gov accessed on 1 September 2024), as recently reviewed by Raeber et al. [112]. This evidence concerns the gene CD8A and neoplasm.